Original Title: White House Spokesperson Psaki was infected with the new crown and met with Biden a few days ago
According to comprehensive reports, on October 31, the US White House spokesperson Psaki confirmed that he was infected with the new crown virus. Psaki said that the last time she met with U.S. President Biden was on October 26 and did not visit Europe with him.
On the other hand, the U.S. Food and Drug Administration (FDA) informed Modena that more time is needed to complete the evaluation of the company’s vaccine for 12 to 17-year-olds.
[White House Spokesperson Psaki Infects New Crown]
Biden had previously traveled to Rome to attend the Group of 20 (G20) Leadership Summit, and will travel to Glasgow on November 1 to attend the 26th Conference of the Parties to the United Nations Framework Convention on Climate Change (COP26).
Psaki, 42, originally planned to travel with Biden, but cancelled the trip after learning that her family was infected. Psaki issued a statement saying: “Since then, I have been quarantined from the 27th to the 30th and performed a PCR test. The result was negative, but today (October 31) I was diagnosed.”
Psaki said that the last time she met with Biden was on October 26, when the two met at the White House and kept a distance of 6 feet (about 180 cm) and wore masks. She said that she currently has only mild symptoms of the infection.
This time, White House Deputy Spokesperson Karine Jean-Pierre accompanied Biden on the visit. Psaki said that after the 10-day quarantine period is over and a quick test is negative, she will return to work.
The White House staff and entourage who accompanied Biden to Europe were screened every day before leaving the White House and were fully vaccinated. Due to close contact with people and frequent business trips for their duties, many officials have been vaccinated with boosters.
Modena said on October 31 that the U.S. Food and Drug Administration (FDA) will need more time to complete the evaluation of the company’s new crown vaccine for adolescents aged 12 to 17.
The company said in a statement that the FDA notified the company that this review may not be completed before January 2022, which may set back the progress of the emergency use authorization (EUA) for this age group.
Modena said the company was told that the FDA needed additional time to evaluate a recent international analysis of the risk of post-vaccination myocarditis, a rare side effect that mainly affects young men.
Modena said it is reviewing a new external analysis of the increased risk of myocarditis in people under the age of 18.
In June of this year, Modena applied to the United States for an emergency use authorization for the vaccine for people aged 12 to 17. Currently, only Pfizer vaccines are available for Americans this year.
Modena also said that while the FDA completes its review of applications for 12 to 17 years of age, it will postpone the submission of EUA applications for children aged 6-11 with a half-dose vaccine for children.
.